DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4+ T cells and CD8+ T cells

Cancer Science

Volumn 96, Issue 10, 2005, Pages 695-705

  Miyazaki, Masafumi ^a   Nakatsura, Tetsuya ^a   Yokomine, Kazunori ^a   Senju, Satoru ^a   Monji, Mikio ^a   Hosaka, Seiji ^a   Komori, Hiroyuki ^a   Yoshitake, Yoshihiro ^a   Motomura, Yutaka ^a   Minohara, Motozumi ^b   Kubo, Tatsuko ^a   Ishihara, Keiichi ^c   Hatayama, Takumi ^c   Ogawa, Michio ^a   Nishimura, Yasuharu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 105; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL GROWTH; CELL TRANSFER; COLORECTAL CANCER; CONTROLLED STUDY; DRUG TARGETING; IMMUNOGENICITY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; FEMALE; HSP110 HEAT-SHOCK PROTEINS; IMMUNOTHERAPY; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; SKIN NEOPLASMS; VACCINES, DNA;

EID: 28444440577     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00093.x     Document Type: Article

References (39)

1. Nakatsura T, Senju S, Yamada K, Jotsuka T, Ogawa M, Nishimura Y. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun 2001; 281: 936-44.
2. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002; 32: 826-36.
3. Monji M, Senju S, Nakatsura T et al. Head and neck cancer antigens recognized by the humoral immune system. Biochem Biophys Res Commun 2002; 294: 734-41.
4. Monji M, Nakatsura T, Senju S et al. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res 2004; 10: 6047-57.
5. Kai M, Nakatsura T, Egami H, Senju S, Nishimura Y, Ogawa M. Heat shock protein 105 is overexpressed in a variety of human tumors. Oncol Rep 2003; 10: 1777-82.
6. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002; 20: 395-425.
7. Hickman-Miller HD, Hildebrand WH. The immune response under stress. The role of HSP-derived peptides. Trends Immunol 2004; 25: 427-33.
8. Manjili MH, Henderson R, Wang XY et al. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res 2002; 62: 1737-42.
9. Wang XY, Chen X, Manjili MH, Repasky E, Henderson R, Subjeck JR. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100. Cancer Res 2003; 63: 2553-60.
10. Wang XY, Li Y, Manjili MH, Repasky EA, Pardoll DM, Subjeck JR. Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor. Cancer Immunol Immunother 2002; 51: 311-9.
11. Lee-Yoon D, Easton D, Murawski M, Burd R, Subjeck JR. Identification of a major subfamily of large hsp70-like proteins through the cloning of the mammalian 110-kDa heat shock protein. J Biol Chem 1995; 270: 15725-33.
12. Yasuda K, Nakai A, Hatayama T, Nagata K. Cloning and expression of murine high molecular mass heat shock proteins, HSP105. J Biol Chem 1995; 270: 29718-23.
13. Ishihara K, Yasuda K, Hatayama T. Molecular cloning, expression and localization of human 105 kDa heat shock protein, hsp105. Biochim Biophys Acta 1999; 1444: 138-42.
14. Hattori K, Matsushita R, Kimura K, Abe Y, Nakashima E. Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth. Biol Pharm Bull 2001; 24: 1214-7.
15. Nakatsura T, Kageshita T, Ito S et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004; 10: 6612-21.
16. Yoshitake Y, Nakatsura T, Monji M et al. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res 2004; 10: 6437-48.
17. Nakatsura T, Komori H, Kubo T et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004; 10: 8630-40.
18. Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y, Nishimura Y. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination. J Immunol 2004; 172: 776-86.
19. Maruyama H, Higuchi N, Nishikawa Y et al. High-level expression of naked DNA delivered to rat liver via tail vein injection. J Gene Med 2002; 4: 333-41.
20. Hylander BL, Chen X, Graf PC, Subjeck JR. The distribution and localization of hsp110 in brain. Brain Res 2000; 869: 49-55.
21. Dummer W, Niethammer AG, Baccala R et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002; 110: 185-92.
22. Maine GN, Mule JJ. Making room for T cells. J Clin Invest 2002; 110: 157-9.
23. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-4.
24. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
25. Kawakami Y, Eliyahu S, Delgado CH et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91: 6458-62.
26. Chen YT, Gure AO, Tsang S et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998; 95: 6919-23.
27. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7.
28. Kumar V, Sercarz E. Genetic vaccination: the advantages of going naked. Nat Med 1996; 2: 857-9.
29. Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 1999; 18: 765-77.
30. Jager E, Chen YT, Drijfhout JW et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265-70.
31. Wakatsuki T, Hatayama T. Characteristic expression of 105-kDa heat shock protein (HSP105) in various tissues of nonstressed and heat-stressed rats. Biol Pharm Bull 1998; 21: 905-10.
32. Hatayama T, Yasuda K. Association of HSP105 with HSC70 in high molecular mass complexes in mouse FM3A cells. Biochem Biophys Res Commun 1998; 248: 395-401.
33. Yamagishi N, Nishihori H, Ishihara, K, Ohtsuka K, Hatayama T. Modulation of the chaperone activities of Hsc70/Hsp40 by Hsp105alpha and Hsp105beta. Biochem Biophys Res Commun 2000; 272: 850-5.
34. Hatayama T, Yamagishi N, Minobe E, Sakai K. Role of hsp105 in protection against stress-induced apoptosis in neuronal PC12 cells. Biochem Biophys Res Commun 2001; 288: 528-34.
35. Manjili MH, Wang XY, Chen X et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 2003; 171: 4054-61.
36. + T cell to a fully functional tumor killer cell. Cancer Res 2002; 62: 6438-41.
37. + T cells. Immunity 2005; 22: 371-83.
38. Zugel U, Schoel B, Yamamoto S, Hengel H, Morein B, Kaufmann SH. Cross recognition by CD8 T cell receptor alpha beta cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 which share intermediate sequence homology. Eur J Immunol 1995; 25: 451-8.
39. Faure O, Graff-Dubois S, Bretaudeau L et al. Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Int J Cancer 2004; 108: 863-70.